title: Subcutaneous ril-2 in advanced melanoma and kidney carcinoma.
abstract: The aim of the present study was to verify the efficacy and tolerability of a treatment protocol using subcutaneous administration of rIL-2. Eighteen patients with metastatic disease were treated: 10 with renal carcinoma and 8 with malignant melanoma. The drug was administered as follows: 9 million UI/mq twice daily for two days followed by 1.8 million UI/mq twice daily for five days/week for six consecutive weeks. Of the 15 patients evaluated for clinical response, all completed treatment without rIL-2 dose modifications. No complete response was obtained. One patient with malignant melanoma and 1 with renal carcinoma (13%) had partial response (soft tissue and lymph nodes respectively) which lasted 3 and 4 months. Six patients with renal carcinoma and 3 melanoma patients had stable disease (60%) which lasted 6 months (median). Toxicity was moderate and spontaneously reversing after stopping treatment. Haemato-immunological modifications and pharmacokinetic study of this modality of rIL-2 treatment were also examined.
authors.affiliation: ONCOL INST,IMMUNOL LAB,BARI,ITALY. ONCOL INST,RIA LAB,BARI,ITALY.
authors.forename: M
authors.initials: M
authors.lastname: Delena
authors.forename: M
authors.initials: M
authors.lastname: Guida
authors.forename: A
authors.initials: A
authors.lastname: Casamassima
authors.forename: L
authors.initials: L
authors.lastname: Addabbo
authors.forename: I
authors.initials: I
authors.lastname: Abbate
authors.forename: M
authors.initials: M
authors.lastname: Correale
authors.forename: M
authors.initials: M
authors.lastname: Musci
authors.forename: V
authors.initials: V
authors.lastname: Lorusso
authors.forename: A
authors.initials: A
authors.lastname: Latorre
authors.forename: A
authors.initials: A
authors.lastname: Mastria